$39.00
Manufacturer: Ukraine
Purpose: Prevents blood clots by inhibiting clotting factors. Treats deep vein thrombosis.
Description
Flenox (enoxaparin sodium) solution for injections 8000ME/0.8 ml. №2 syringe
Ingredients
Active ingredient: Enoxaparin sodium
Dosage
Dosage: The usual dose of Flenox is **80 mg** injected subcutaneously once daily. Dosage may vary based on the condition being treated. Always follow your healthcare provider’s instructions.
Indications
Indications: Flenox is indicated for the prevention of deep vein thrombosis (DVT) which may lead to pulmonary embolism in patients undergoing surgery.
Contraindications
Contraindications: Do not use Flenox if you are allergic to enoxaparin sodium or any other ingredients in the product. It is also contraindicated in patients with active major bleeding.
Directions
Directions: Flenox is for subcutaneous use only. Do not administer intramuscularly. Rotate injection sites to prevent irritation. Follow proper injection techniques as instructed by your healthcare provider.
Scientific Evidence
Flenox (enoxaparin sodium) has been extensively studied for its efficacy in preventing thromboembolic events. Research published in the *New England Journal of Medicine* has shown that enoxaparin significantly reduces the risk of DVT in surgical patients compared to unfractionated heparin.
Additional Information
It is important to monitor for signs of bleeding while on Flenox therapy. Report any unusual bleeding or bruising to your healthcare provider immediately. Inform all healthcare professionals about your Flenox use before any medical procedures.
Pharmacological Effects: Enoxaparin sodium works by inhibiting the formation of blood clots. It acts as an anticoagulant by enhancing the inhibition of factor Xa, thereby preventing the conversion of prothrombin to thrombin.
Clinical Trials: Clinical trials have demonstrated the effectiveness of enoxaparin sodium in preventing thromboembolic events in various patient populations. A study published in the *Journal of Thrombosis and Haemostasis* showed that enoxaparin was well-tolerated and effective in preventing DVT in cancer patients undergoing surgery.
Recent Reviews